BOSTON, Aug. 18 /PRNewswire/ -- China PharmaHub Corp.
("PharmaHub"), recently merged with World Wide Relics (OTC Bulletin
Board: WRLC), which will be shortly changing its name to China
PharmaHub Corp, is proud to announce it has signed a cooperation
agreement with Chengdu Yongkon Pharmacy Co. Ltd., ("Yongkon"), a
pharmaceutical company based in Sichuan, with an established sales network of
over 2600 hospitals in China.
PharmaHub was authorized by Yongkon as its appointed agent to
identify pharmaceutical products and medical devices in the U.S.
and negotiate the terms to obtain the rights to sell such products
and devices in China.
Yongkon is an established and GMP certified pharmaceutical
company with focus on the identification, development, manufacture,
sales and distribution of Chinese traditional medicine,
biopharmaceuticals and medical equipment with its focus on
antiviral drugs, bio-engineering drugs and anticancer drugs.
Yongkon manufactures and sells over 90 GMP approved drugs in
China. Its leading product,
Xiaojinwan, is a well known Traditional Chinese Medicine treating
breast hyperplasia, thyroid and benign tumor. Yongkon has a
marketing force of over 400 sales personnel in 34 sales offices in
over 31 provinces and cities as well as in Beijing, Tianjin, Shanghai and Chongqing.
Richard Lui, CEO of PharmaHub,
said "We are glad to gain another capable strategic partner in
China. In less than one year of
founding, we have successfully established partnerships with
Research Institute and Government Agencies in China. We have now taken an important step in
the partnership with entrepreneurs. With the accomplishment
of this major milestone, we've successfully created a chain of
command in the commercialization of technologies we identify and
bring to China. Yongkon
supports our structure with an established sales and marketing team
and nationwide sales channel."
Lui continued, "This is another successful demonstration of our
HUB model, of partnering with successful enterprises and working
together to bring life saving pharmaceuticals and medical devices
to the world. PharmaHub's relationships with the New Drug
Center and the Sichuan Technical Exchange Center, and now with
Chengdu Yongkon, represent PharmaHub's drive to become an
innovator in the pharmaceutical and medical device industry."
About PharmaHub:
China PharmaHub Corp. is engaged in the business of licensing,
developing and the commercialization of pharmaceutical and
healthcare products and technologies between Chinese pharmaceutical
companies and other pharmaceutical companies located worldwide,
with initial emphasis in the United
States and Europe.
Management believes that PharmaHub brings a unique wealth of
resources to assist scientists and companies in bringing their
ideas to reality. PharmaHub's corporate headquarters are
located in California, with
offices in Boston and China. For more information visit
www.chnpharmahub.com .
|
Contact:
|
|
|
Monica Ding
|
|
|
Chief Financial
Officer
|
|
|
Tel: (909)
843-6288
|
|
|
Email:
ir@chnpharmahub.com
|
|
|
Forward-Looking Statements
This press release, together with other statements and
information publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. The Company
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Except as otherwise required by the federal securities
laws, the Company disclaims any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein.
SOURCE China PharmaHub Corp.
Copyright . 18 PR Newswire